FY2026 EPS Forecast for Dare Bioscience Increased by Analyst

Dare Bioscience, Inc. (NASDAQ:DARE – Free Report) – Equities research analysts at Brookline Capital Markets boosted their FY2026 EPS estimates for Dare Bioscience in a research report issued to clients and investors on Monday, November 16th. Brookline Capital Markets analyst K. Dolliver now forecasts that the biotechnology company will post earnings of ($0.83) per share for the year, up from their prior estimate of ($0.92). The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.68) per share. Brookline Capital Markets also issued estimates for Dare Bioscience’s Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.56) EPS.

Other research analysts have also issued research reports about the stock. UBS Group set a $1.00 target price on shares of Dare Bioscience in a research report on Monday, September 14th. Ladenburg Thalmann & Co. Inc. assumed coverage on shares of Dare Bioscience in a research report on Monday, October 26th. They issued a “buy” rating and a $2.00 price target for the company. Benchmark reiterated a “buy” rating on shares of Dare Bioscience in a research note on Monday, August 17th. HC Wainwright reiterated a “buy” rating on shares of Dare Bioscience in a research note on Monday, August 17th. Finally, Weiss Ratings downgraded Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Dare Bioscience has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Get Our Latest Stock Report on Dare Bioscience

Dare Bioscience Trading Down 9.8%

Shares of Dare Bioscience stock opened at $0.41 on Thursday. Dare Bioscience has a twelve month low of $0.41 and a twelve month high of $3.78. The company has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $1.47.

Dare Bioscience (NASDAQ:DARE – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Dare Bioscience had a negative net margin of 748.97% and a negative return on equity of 1,052.83%. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $2.04 million.

Dare Bioscience Company Profile

(Get Free Report)

Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.

Recommended Stories

Earnings History and Estimates for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.